<DOC>
	<DOCNO>NCT00022425</DOCNO>
	<brief_summary>RATIONALE : Chemoprevention therapy use certain drug try prevent recurrence cancer . The use perillyl alcohol may effective prevent recurrence breast cancer . PURPOSE : Phase I trial study effectiveness perillyl alcohol prevent recurrence breast cancer woman treat surgery without adjuvant therapy .</brief_summary>
	<brief_title>Perillyl Alcohol Preventing Recurrent Breast Cancer Women Who Have Been Treated With Surgery With Without Adjuvant Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose perillyl alcohol woman risk recurrent breast cancer . - Determine toxicity drug patient . - Determine single-dose multiple-dose pharmacokinetics drug patient . OUTLINE : This dose-escalation study . Patients receive oral perillyl alcohol daily day 1-28 . Treatment continue every 4 week 3 course . Cohorts 6 patient receive escalate dos perillyl alcohol maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 6 patient experience grade 1 toxicity least 1 6 patient experience grade 2 great toxicity . Patients follow weekly . PROJECTED ACCRUAL : A total 24 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ethanol</mesh_term>
	<mesh_term>Perilla alcohol</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Personal history stage Tis , I , II , IIIA breast cancer Previously treat definitive resection curative intent Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Female Menopausal status : Not specify Performance status : ECOG 01 Life expectancy : Not specify Hematopoietic : WBC least 3,000/mm3 Platelet count least 100,000/mm3 Hemoglobin least 9.0 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST ALT great 1.5 time upper limit normal ( ULN ) Alkaline phosphatase great 1.5 time ULN Renal : Creatinine great 1.6 mg/dL Other : No known malabsorption syndrome No contraindication perillyl alcohol No hypersensitivity citrus soybean product No nonbreast malignancy within past 2 year except nonmelanoma skin cancer carcinoma situ No active malignancy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : At least 6 month since prior chemotherapy Endocrine therapy : Concurrent adjuvant hormonal therapy allow Radiotherapy : At least 6 month since prior radiotherapy Surgery : See Disease Characteristics At least 6 month since prior surgery At least 2 year since prior primary surgery More 4 week since prior surgery require general anesthesia , include breast reconstructive surgery Other : More 3 month since prior enrollment singledose study perillyl alcohol More 3 month since prior enrollment current study ( low dose level ) No concurrent vitamin supplement except daily multivitamin ( recommended daily allowance )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2003</verification_date>
	<keyword>recurrent breast cancer</keyword>
</DOC>